RVMD Revolution Medicines

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.

Details of the company’s participation are as follows:

  • Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

    Conference Dates: February 7-8, 2024

    Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, February 7, 2024

    Location: New York, NY; webcast available
  • TD Cowen 44th Annual Health Care Conference

    Conference Dates: March 4-6, 2024

    Fireside Chat Time/Date: 2:10 p.m. Eastern on Wednesday, March 6, 2024

    Location: Boston, MA; webcast available

To access the live webcasts of the presentations, please visit the “Events & Presentations” page of Revolution Medicines’ website at . Additionally, replays of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following each conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).



Revolution Medicines Media & Investor Contact:
Erin Graves
650-779-0136
 
EN
01/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Revolution Medicines

Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
 PRESS RELEASE

Revolution Medicines Reports Second Quarter 2025 Financial Results and...

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasibCompany entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercializationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Ti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch